425: Runway Growth to Acquire SWK Holdings, Boosts Healthcare Portfolio

Runway Growth Finance Corp. announces a definitive merger agreement to acquire SWK Holdings Corporation, aiming to expand its healthcare and life sciences portfolio and enhance financial metrics.

Summary

• Runway Growth Finance Corp. (RWAY) has entered into a definitive merger agreement to acquire SWK Holdings Corporation (SWK).
• The transaction is structured as a NAV-for-NAV merger, a tax-free reorganization, with an estimated purchase price of approximately $220 million.
• Consideration includes approximately $145 million in cash and $75.5 million in RWAY shares, plus an additional $9 million cash payment from Runway Growth Capital LLC to SWK stockholders.
• The acquisition is anticipated to close in late Q4-2025 or early Q1-2026.
• The merger is expected to significantly expand RWAY's healthcare and life sciences portfolio, increasing its representation from 14% to approximately 31% of the total loan portfolio.
• The combined entity will have approximately $1.267 billion in investments at fair value and 76 portfolio companies, reducing RWAY's average loan size and improving portfolio diversification.

Sentiment

Score: 8

Explanation: The filing presents a highly positive outlook on a strategic acquisition, detailing significant financial and operational benefits, including NII accretion, portfolio diversification, and enhanced market position. While standard risks are disclosed, the overall tone and projected outcomes are strongly favorable for Runway Growth Finance Corp.

Positives

• Optimizes RWAY's portfolio through increased diversification and scale.
• Expands RWAY's presence and investment capabilities in the attractive healthcare and life sciences sectors.
• Capitalizes on the benefits of the BC Partners Credit platform, enhancing infrastructure for multi-faceted growth.
• Expected to generate mid single-digit run-rate Net Investment Income (NII) accretion during the first full quarter post-closing.
• Anticipated improvements in trading liquidity due to a broadened shareholder base and increased market capitalization.
• Lower risk profile with the average loan position declining to approximately 2% of the total portfolio.
• Reduced funding costs and increased viability of accessing ABS and other credit markets.
• More efficient use of leverage, expanding Return on Equity (ROE) and NII profile, contributing to expanded base dividend coverage.
• SWK brings deep sector expertise, strong management, and a proven origination track record in healthcare.
• The combined platform will have approximately $10 billion in AUM and 172 professionals, positioning RWAY as a destination for growth investment.

Risks

• Uncertainty regarding the ability of the parties to consummate the merger on the expected timeline, or at all.
• Risk that expected synergies and savings associated with the merger may not be fully realized.
• Potential inability to realize anticipated benefits of the merger, including the expected elimination of certain expenses and costs.
• Impact of the merger on the depth of trading in RWAY's shares of common stock post-closing.
• Possibility that any or all of the various conditions to the consummation of the merger may not be satisfied or waived.
• Risks related to diverting management's attention from ongoing business operations.
• Uncertainties regarding the combined company's future plans, expectations, objectives, and intentions.
• Potential termination of the merger agreement.
• Risks associated with the future operating results and net investment income projections of the combined company.
• Uncertainty regarding the ability of Runway Growth Capital LLC to implement its future plans with respect to the combined company.
• Challenges in attracting and retaining highly talented professionals for Runway Growth Capital LLC and its affiliates.
• Risks related to the business prospects of the combined company and its portfolio companies.
• Uncertainties regarding expected financings and investments and additional leverage that the combined company may seek to incur in the future.
• Risks concerning the adequacy of the cash resources and working capital of the combined company.
• Risk that stockholder litigation in connection with the merger may result in significant costs of defense and liability.

Future Outlook

Runway Growth Finance anticipates the acquisition to generate mid single-digit run-rate Net Investment Income (NII) accretion during the first full quarter following the closing of the transaction. The merger is expected to enhance the company's financial profile, improve trading liquidity, lower its risk profile, reduce funding costs, and enable more efficient use of leverage, contributing to expanded base dividend coverage. The combined entity aims to execute on organic and inorganic growth strategies, leveraging an expanded platform and increased capabilities in healthcare and life sciences.

Management Comments

• This transaction advances Runway Growth's strategy to optimize our portfolio through diversification and scale, expand in attractive industry sectors like healthcare and life sciences, capitalize on the benefits of the BC Partners Credit platform, and increase NII levels to ensure consistency in our capital allocation strategy.
• The acquisition of SWK solidifies RWAY's position as a lender to this large and growing market – healthcare and life sciences will represent approximately 31% of our total loan portfolio post transaction.
• This transaction demonstrates that Runway represents a destination for growth investment, can utilize M&A as an attractive growth lever, and has established a blueprint for future expansion.

Industry Context

The acquisition positions Runway Growth Finance Corp. to significantly expand its footprint in the high-growth healthcare and life sciences sectors, which are characterized by pervasive demand and minimal correlation with economic cycles. This strategic move aligns with a broader industry trend of financial institutions seeking specialized, defensible assets with high barriers to entry and attractive risk-adjusted returns. By integrating SWK Holdings' expertise and portfolio, Runway enhances its competitive edge in providing structured debt and hybrid financing solutions to commercial-stage healthcare companies, leveraging FDA-approved assets for superior risk-reward outcomes.

Comparison to Industry Standards

• The combined platform's AUM of approximately $10 billion is stated to be over 2x the closest standalone venture debt peer, indicating a significant scale advantage within the venture debt market.
• SWK's historical focus on $5-$25 million financings with unlevered, mid-teens gross returns suggests a strong performance in its niche, which Runway aims to integrate and potentially enhance.
• The strategic focus on FDA-approved assets with high barriers to entry is a common strategy in life sciences finance to ensure defensible assets and limited downside, aligning with best practices for risk mitigation in specialized lending.

Legal Proceedings

• Stockholder litigation in connection with the merger may result in significant costs of defense and liability.

Related Party Transactions

• An additional $9 million cash payment from Runway Growth Capital LLC in its capacity as RWAY's external investment adviser for distribution to stockholders of SWK.

Stakeholder Impact

• Shareholders (RWAY): Expected NII accretion, improved trading liquidity, increased market cap, expanded base dividend coverage, and a more diversified, lower-risk portfolio.
• Shareholders (SWK): Will receive cash and RWAY shares as consideration for their holdings.
• Employees (SWK): Key members of SWK's investment team are expected to join RWAY's broader investment team.
• Customers/Portfolio Companies: The combined entity will offer expanded capabilities and a larger platform for financing.

Next Steps

• Runway will file a Combined Proxy Statement and Prospectus with the SEC.
• SWK stockholders are urged to read the Combined Proxy Statement and Prospectus and other related SEC filings.
• Anticipated closing of the merger in late Q4-2025 or early Q1-2026.
• Runway Growth Capital LLC and its affiliates will continue efforts to attract and retain highly talented professionals.
• The combined company may seek to incur expected financings and investments and additional leverage in the future.

Key Dates

Recommendation

The proposed acquisition of SWK Holdings by Runway Growth Finance Corp. is highly strategic and accretive, positioning RWAY for significant growth in the attractive healthcare and life sciences sectors. The transaction is expected to drive mid single-digit NII accretion, enhance portfolio diversification, reduce risk, and improve liquidity. The combined entity's increased scale and specialized expertise, particularly in FDA-approved assets, suggest a stronger financial profile and improved competitive positioning. While merger-related risks exist, the outlined benefits and the favorable industry context make this a compelling long-term investment opportunity.

Keywords

Runway Growth Finance, SWK Holdings, Merger, Acquisition, Healthcare Finance, Life Sciences, BDC, Specialty Finance, Portfolio Diversification, NII Accretion, BC Partners Credit, SEC Filing